The International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) Microphysiological Systems (MPS) Affiliate is a group of pharmaceutical industry scientists who seek to expedite appropriate characterization and incorporation of MPS to potentially improve drug safety assessment and provide safer and more effective medicines to patients. The IQ MPS Affiliate (formed in June of 2018), was formerly a Working Group (WG) of the IQ Consortium (https://iqconsortium.org) created at the request of the NIH National Center for Advancing Translational Science (NCATS) with a mission for pharmaceutical companies to work collaboratively with NCATS funded tissue chip developers to advance MPS, for improving the understanding of human pharmacology and the predictivity of safety and toxicology translation. In order to broaden impact and provide a venue for appropriate cross-pharma collaboration and data sharing to facilitate industry implementation and qualification of MPS models, the IQ MPS WG transitioned to an IQ Affiliate in 2018. This session will provide an update on IQ MPS Affiliate’s accomplishments and share future aims.
1. Learn about the current status of microphysiological systems in drug discovery and development
2. Learn about collaborative efforts within Pharma
3. Learn about importance of human and animal cell based microphysiological systems in drug discovery and development